Navigation Links
Pinnacle Biologics Announces Stock Purchase Agreement With MedImmune
Date:6/25/2008

ROCKVILLE, Md., June 26 /PRNewswire/ -- Pinnacle Biologics, a private, full service pharmaceutical and biotech solutions company, today announced that it has entered into a preferred stock purchase transaction with MedImmune, LLC, pursuant to which MedImmune has acquired certain unspecified number of preferred stock shares of Pinnacle Biologics, Inc. The terms of the agreement were not disclosed.

Pinnacle Biologics owns the marketing and distribution rights to MedImmune's Ethyol(R), 50 mg/ml, powder for solution for infusion in Western Europe, Turkey and Israel.

"This is a highpoint for Pinnacle, as it signifies an additional milestone for our company," said Guillermo Herrera, Chairman of the Board of Pinnacle Biologics.

About Pinnacle Biologics

Founded in 2007 by health care executives Guillermo Herrera, James Miller, and Viren Grover, Pinnacle Biologics is a premier international company that excels in assisting pharmaceutical and biotech companies that require a total solution in either launching products or maximizing/monetizing the value of products late in their life cycle. Pinnacle forms exclusive relationships with research-based pharmaceutical multi-national corporations and biotechnology companies to take products to the next level.

Pinnacle provides a full range of services including regulatory, sales, marketing, distribution (including billing and collections), pharmacovigilence, product safety, market research and administrative services.

Website: http://www.pinnaclebiologics.com

COMPANY CONTACT:

James R. Miller, Pinnacle

President & CEO

1 (240) 372-4599


'/>"/>
SOURCE Pinnacle Biologics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Pinnacle Biologics Announces Contract With Chiltern
2. Pinnacle Biologics Announces Logistics Services Agreement With the Movianto Group
3. Dermatologists Report Increased Use of Biologics in the Treatment of Psoriasis
4. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
5. QSV Biologics awarded cGMP manufacturing contract by Pfizer Inc.
6. Insmed to Present at CBI Follow-On Biologics Conference
7. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
8. Biologics, Derma Fillers are Key to Dermatological Drug Market Growth
9. Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics
10. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
11. MedImmune Submits Biologics License Application to FDA for Motavizumab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... ... clinics and IVF laboratories. A contingency of reproductive endocrinologists, including Dr. George ... women experiencing infertility and to help them build families. , Ovation Fertility is ...
(Date:5/2/2016)... CA (PRWEB) , ... May 02, 2016 , ... StarNet ... solutions today announced the addition of three Secure Remote Desktop modules to its flagship ... remote desktops from Linux and Unix servers to the user’s PC over encrypted SSH. ...
(Date:4/29/2016)... ... April 29, 2016 , ... Proove ... excited to announce the launch of the Proove Health Foundation . The ... education to promote the use of personalized medicine for tackling the nation’s most-pressing ...
(Date:4/29/2016)... CO (PRWEB) , ... April 29, 2016 , ... ... addressing the necessary fundamentals to transform technology into a viable company, CereScan’s CEO, ... growth. Mr. Kelley, a recognized leader and mentor in the Denver area ...
Breaking Biology Technology:
(Date:3/11/2016)... -- --> --> ... Market by Technology (Pattern Recognition), by Component (Hardware, Software, ... (On-Premises and Cloud), by Industry Vertical and by Region ... global market is expected to grow from USD 12.49 ... at a CAGR of 19.1%. , ...
(Date:3/9/2016)... This BCC Research report provides an overview ... Sequencing (RNA Seq) market for the years 2015, 2016 ... reagents, data analysis, and services. Use this ... market such as RNA-Sequencing tools and reagents, RNA-Sequencing data ... each segment and forecast their market growth, future trends ...
(Date:3/8/2016)...   Valencell , the leading innovator in ... secured $11M in Series D financing. The investment ... fund being launched by UAE-based financial services company ... TDF Ventures and WSJ Joshua Fund. Valencell plans ... growth and accelerate its pioneering innovation in accurate ...
Breaking Biology News(10 mins):